Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Rev. chil. infectol ; 29(2): 149-155, abr. 2012. graf, tab
Artigo em Espanhol | LILACS | ID: lil-627227

RESUMO

Objective: To describe antifungal susceptibility testing surveillance (December 2004-September 2010) in Candida spp., for amphotericin B, fluconazole and voriconazole, at the Laboratorio de Microbiología, Pontificia Universidad Católica de Chile. Method: The study was performed utilizing E test and included yeasts from invasive origin and isolates in which antifungal susceptibility testing was asked for by the patient's physician. Results: The yeasts were mainly recovered from urine samples (n: 64), blood cultures (n: 51) and secretions (n: 24). Two hundred ninety three isolates were studied: C. albicans (38%), C. glabrata (30%), C. tropicalis (11%), C. parapsilosis (10%), C. krusei (4%) and others (7%). All Candida species were 100% susceptible to amphotericin B, except C. krusei (1/12). Fluconazole's global susceptibility in C. albicans was 91.8%, but 100% in isolates from blood cultures versus 76% in isolates from urine. C. tropicalis was 93.9% susceptible to fluconazole, C. parapsilosis, 90% and C. glabrata 30.3%. C. krusei had no susceptible isolates to fluconazole. Voriconazole resistance was mainly present in C. glabrata (11.5%). Conclusions: We recommend the study of antifungal susceptibility in isolates from invasive origin, selected urine strains and C. glabrata. Fluconazole remains effective in C. albicans from blood.


Objetivo: Describir la susceptibilidad antifúngica in vitro (anfotericina B, fluconazol y voriconazol) de aislados de Candida spp., observada desde diciembre 2004 a septiembre 2010 en el Laboratorio de Microbiología de la Pontificia Universidad Católica de Chile. Material y Método: Se realizó estudio de susceptibilidad mediante E test® a todas las cepas invasoras y a aquellas en que se solicitara dirigidamente antifungigrama (aislados locales o derivados desde otros centros). Resultados: Se estudiaron 293 aislados, principalmente de muestras de orina (n: 64), hemocultivos (n: 51) y secreciones (n: 24). Las especies correspondieron a C. albicans (38%), C. glabrata (30%), C. tropicalis (11%), C. parapsilosis (10%), C. krusei (4%) y otras (7%). Hubo 100% de susceptibilidad a anfotericina B, excepto en C. krusei (1/12 resistente). La susceptibilidad a fluconazol fue: C. albicans 91,8% (100% en aislados de sangre vs 76% en orina); C. tropicalis, 93,9%, C. parapsilosis, 90% y C. glabrata 30,3%. Candida krusei, no tuvo aislados susceptibles a fluconazol. La resistencia a voriconazol se evidenció fundamentalmente en C. glabrata (11,5%). Conclusiones: Recomendamos realizar estudio de susceptibilidad en aislados de muestras invasoras, casos seleccionados de cepas de orina y ante sospecha de C. glabrata. Fluconazol mantiene efectividad en C. albicans proveniente de sangre.


Assuntos
Humanos , Anfotericina B/farmacologia , Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Fluconazol/farmacologia , Pirimidinas/farmacologia , Triazóis/farmacologia , Chile , Estudos de Coortes , Candida/classificação , Candida/isolamento & purificação , Farmacorresistência Fúngica , Testes de Sensibilidade Microbiana , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA